Compare WLYB & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLYB | SDGR |
|---|---|---|
| Founded | 1807 | 1990 |
| Country | United States | United States |
| Employees | 5200 | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 856.7M |
| IPO Year | N/A | 2020 |
| Metric | WLYB | SDGR |
|---|---|---|
| Price | $36.71 | $12.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $21.13 |
| AVG Volume (30 Days) | 230.0 | ★ 1.1M |
| Earning Date | 03-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $0.02 | $6.11 |
| Revenue Next Year | $2.32 | $7.69 |
| P/E Ratio | $15.27 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $29.16 | $11.11 |
| 52 Week High | $45.16 | $27.63 |
| Indicator | WLYB | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 43.19 |
| Support Level | $36.20 | $11.11 |
| Resistance Level | $38.63 | $13.36 |
| Average True Range (ATR) | 0.33 | 0.64 |
| MACD | 0.60 | 0.09 |
| Stochastic Oscillator | 94.35 | 41.60 |
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.